Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 2
Abstract
The application of modeling and simulation techniques is increasingly common in preclinical stages of the drug discovery and development process. A survey focusing on preclinical pharmacokinetic/pharmacodynamics (PK/PD) analysis was conducted across pharmaceutical companies that are members of the International Consortium for Quality and Innovation in Pharmaceutical Development. Based on survey responses, ~68% of companies use preclinical PK/PD analysis in all therapeutic areas indicating its broad application. An important goal of preclinical PK/PD analysis in all pharmaceutical companies is for the selection/optimization of doses and/or dose regimens, including prediction of human efficacious doses. Oncology was the therapeutic area with the most PK/PD analysis support and where it showed the most impact. Consistent use of more complex systems pharmacology models and hybrid physiologically based pharmacokinetic models with PK/PD components was less common compared to traditional PK/PD models. Preclinical PK/PD analysis is increasingly being included in regulatory submissions with ~73% of companies including these data to some degree. Most companies (~86%) have seen impact of preclinical PK/PD analyses in drug development. Finally, ~59% of pharmaceutical companies have plans to expand their PK/PD modeling groups over the next 2 years indicating continued growth. The growth of preclinical PK/PD modeling groups in pharmaceutical industry is necessary to establish required resources and skills to further expand use of preclinical PK/PD modeling in a meaningful and impactful manner.
Authors and Affiliations
Edgar Schuck, Tonika Bohnert, Arijit Chakravarty, Valeriu Damian-Iordache, Christopher Gibson, Cheng-Pang Hsu, Tycho Heimbach, Anu Shilpa Krishnatry, Bianca M Liederer, Jing Lin, Tristan Maurer, Jerome T Mettetal, Daniel R Mudra, Marjoleen JMA Nijsen, Joseph Raybon, Patricia Schroeder, Virna Schuck, Satyendra Suryawanshi, Yaming Su, Patrick Trapa, Alice Tsai, Majid Vakilynejad, Shining Wang, Harvey Wong
Keywords
Related Articles
- EP ID EP680933
- DOI 10.1208/s12248-014-9716-2
- Views 69
- Downloads 0
Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging
Molecular imaging techniques for protein therapeutics rely on reporter labels, especially radionuclides or sometimes near-infrared fluorescent moieties, which must be introduced with minimal perturbation of the protein&#...
The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs
While each of the two key parameters of oral drug absorption, the solubility and the permeability, has been comprehensively studied separately, the relationship and interplay between the two have been largely ignored. Fo...
Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans
Repifermin (truncated, recombinant human keratinocyte growth factor-2, KGF-2) was evaluated in cynomolgus monkeys and healthy humans during a phase 1 trial. Monkeys received vehicle or repifermin at 20, 75, or 200 ...
Investigation of the Influence of FcRn on the Distribution of IgG to the Brain
It has been suggested that the neonatal Fc receptor (FcRn) is a primary determinant of the distribution of IgG to the brain. In the present report, 125I-labeled 7E3, a monoclonal IgG1 antibody, was injected intravenously...
Blood pressure as an example of a biomarker that functions as a surrogate
There are many important uses of biomarkers in drug development. An area of particular interest is the use of biomarkers as surrogate end points. Only a small minority of biomarkers are established surrogate end points....